Phase 4 Completed N=28 Randomized Quadruple-blind Prevention

Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial

Delirium · Postoperative cognitive dysfunction

Source: ClinicalTrials.gov NCT00835159 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2014

Primary outcomePrimary: Incidence of POD — 2; 4 participants

Summary

The purpose of this study is to determine whether preoperative administration of Rivastigmine prevents the incidence of postoperative delirium in patients undergoing major surgery as well as postoperative cognitive dysfunction.

Outcome Measures

Outcome	Result	p-value
PRIMARY Incidence of POD	2; 4	—

Eligibility Criteria

Inclusion Criteria

65 ≥ y.o. undergoing major elective surgery over 2 hours in length with one or more of the following:

Preoperative cognitive impairment
Age > 70 y.o.
Use of psychoactive medications
History of prior delirium
Severe illness/co-morbidity

Exclusion Criteria

Delirium on admission Profound dementia No spoken/written English An emergent procedure Hypersensitivity to Rivastigmine

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00835159). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.